Company / Depreciation & Amortization
Revolution Medicines, Inc. Depreciation & Amortization History
FY2018-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Depreciation & Amortization
$5.0M
FY2023
5-year range
$2.3M / $5.0M
FY2019-FY2023
Trend
+91.5%
vs FY2022
Sector context
#78 of 163
Health Care
What the data says
At $5M, Revolution Medicines, Inc.'s depreciation & amortization ranks #86 of 163 in the Health Care sector. Depreciation & Amortization has increased for 3 consecutive years, from $2M in FY2020 to $5M in FY2023.
Based on SEC 10-K filings.
$5M in FY2023 with a 5-year CAGR of +26.1%.
Increased from $2M to $5M over the past 2 years.
Health Care sector context is included.
Depreciation & Amortization over time
Growth rates
- 3-Year CAGR
- +47.3%
- 5-Year CAGR
- +26.1%
- 10-Year CAGR
- -
Sector benchmark
#86 of 163 in Health CareTop 52% of 163This company $5.0M Sector average $219.4M
▼
-97.7% below sector average
Key checks
Key Insights
- Revolution Medicines, Inc.'s depreciation & amortization has grown for 3 consecutive years.
- 5-year CAGR of +26.1%, indicating consistent growth.
- In FY2023, depreciation & amortization increased 91.5% year-over-year.
- Ranks #78 out of 163 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -1.10 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Depreciation & AmortizationValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | $5.0M | +91.5% |
| FY2022 | $2.6M | +14.9% |
| FY2021 | $2.3M | +45.1% |
| FY2020 | $1.6M | -31.1% |
| FY2019 | $2.3M | +45.1% |
| FY2018 | $1.6M | - |
As of FY2023 · SEC 10-K · Updated Jun 30, 2026